The improvement of NASH symptoms by sweroside was accompanied with its inhibitory effects on the hepatic NLRP3 inflammasome as hepatic IL-1β and caspase-1 were decreased. Here, NLRP3 is linked to metabolic dysfunction-associated steatohepatitis.